EUVIMEDDescoperă EUVIMED
VergleichsstudieBeobachtungsstudieKohortenstudieOpen access · CC BY-NC-ND 4.0

Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study

Song-Chou Hsieh, Wei-Sheng Chen, Jui-Chieh Hu, Wan-Yu Sung iD, Wen-Chan Tsai, Hsiang-Cheng Chen, Chung-Ming Huang, Edward Kuo, David Gruben, Yi-Hsing Chen

International Journal of Rheumatic Diseases · 2026

DOI: 10.1111/1756-185x.70653 ↗

At a glance

Vergleichsstudie in International Journal of Rheumatic Diseases, 2026. Written by Song-Chou Hsieh and 9 co-authors. Institution: Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Major MEDLINE topics: Arthritis, Rheumatoid, Piperidines, Pyrimidines, Janus Kinase Inhibitors. 22 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Pfizer.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Aim

To assess the long‐term effectiveness and safety of, and persistence/adherence to, tofacitinib (an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis [RA]) and tumor necrosis factor inhibitors (TNFi) in Taiwanese patients with RA in real‐world settings.

Methods

This was a 5 year, prospective cohort study in Taiwanese patients with RA newly initiating tofacitinib or TNFi. Patients received standard care per treating rheumatologists and fulfillment of National Health Insurance reimbursement criteria. Effectiveness outcomes (baseline and every 24 weeks) included: Disease Activity Score in 28 joints, erythrocyte sedimentation rate; Clinical Disease Activity Index; Health Assessment Questionnaire‐Disability Index; and Work Productivity and Activity Impairment‐RA. Differences between groups were compared using mixed logistic regression models. Safety and persistence/adherence were assessed throughout.

Results

In total, 267 patients were included (tofacitinib, n = 145; TNFi, n = 122). No significant differences in effectiveness outcomes for tofacitinib versus TNFi were reported before or after propensity score adjustment. In patients receiving tofacitinib and TNFi, rates of adverse events (AEs; 56.6% vs. 55.7%), serious AEs (20.0% vs. 21.3%), major adverse cardiovascular events (0% vs. 0.8%), malignancy (2.1% vs. 0.8%), and deaths (1.4% vs. 3.3%) were similar. Serious infections/herpes zoster occurred in 13.1%/12.4% and 8.2%/3.3% of patients receiving tofacitinib and TNFi, respectively. No venous thromboembolism events were reported. Persistence/adherence was comparable between tofacitinib and TNFi.

Conclusion

Tofacitinib effectiveness and persistence/adherence were generally similar to TNFi in this real‐world analysis in Taiwanese patients with RA. Safety outcomes were consistent with the known safety profiles of tofacitinib and TNFi. Trail Registration EUPAS13431.

Subjects

MeSH terms (MEDLINE)

Arthritis, RheumatoidPiperidinesPyrimidinesJanus Kinase InhibitorsTumor Necrosis Factor InhibitorsAntirheumatic AgentsHumansFemaleMaleTreatment OutcomeMiddle AgedTaiwanProspective StudiesTime FactorsAgedMedication AdherenceDisability EvaluationAdultRisk FactorsPyrrolesLogistic Models

Author keywords

TNFireal‐world datarheumatoid arthritistofacitinib

Substances

tofacitinibPiperidinesPyrimidinesJanus Kinase InhibitorsTumor Necrosis Factor InhibitorsAntirheumatic AgentsPyrroles

Authors and institutions

  • Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Medicine, National Taiwan University Cancer Center, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Division of Allergy, Immunology and Rheumatology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
  • Department of Allergy, Immunology, and Rheumatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.

ORCID profiles: Wan-Yu Sung

Funding

  • Pfizer

Cite

APA

Hsieh, S. C., Chen, W. S., Hu, J. C., Sung, W. Y., Tsai, W. C., Chen, H. C., Huang, C. M., Kuo, E., Gruben, D., & Chen, Y. H. (2026). Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70653

Vancouver

Hsieh SC, Chen WS, Hu JC, Sung WY, Tsai WC, Chen HC, et al. Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study. International Journal of Rheumatic Diseases. 2026. doi:10.1111/1756-185x.70653

BibTeX
@article{Hsieh2026,
  author = {Hsieh, Song-Chou and Chen, Wei-Sheng and Hu, Jui-Chieh and Sung, Wan-Yu and Tsai, Wen-Chan and Chen, Hsiang-Cheng and Huang, Chung-Ming and Kuo, Edward and Gruben, David and Chen, Yi-Hsing},
  title = {Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study},
  journal = {International Journal of Rheumatic Diseases},
  year = {2026},
  doi = {10.1111/1756-185x.70653}
}
Start for free →